Sandoz has welcomed the regulatory approval of their denosumab biosimilars ahead of their consideration by the Pharmaceutical Benefits Advisory Committee in November.
Sandoz welcomes regulatory approval of the first denosumab biosimilar in Australia
August 27, 2024 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
NSW Premier opens Australia’s first large-scale health translation hub at UNSW
November 24, 2025 - - Latest News -
Cynata completes final patient visits in pivotal Phase 3 osteoarthritis trial
November 24, 2025 - - Australian Biotech -
New review recommends a balanced and measured approach to adopting AI in clinical practice
November 24, 2025 - - BioPharma -
Sanofi becomes first tenant of ENTRI, marking major step for Queensland’s translational research ambitions
November 24, 2025 - - Latest News -
Moderna names CSIRO scientist Dr Anne Klein as 2025 Australian Fellow
November 24, 2025 - - Australian Biotech -
‘Trojan Horse’ treatment offers hope for Australians facing relapsed multiple myeloma
November 24, 2025 - - Latest News -
New national report warns of deepening ovarian cancer burden and calls for urgent action
November 24, 2025 - - Latest News
